Holdings

Catalio Capital Management, LP

As of Sep 30, 2026, Catalio Capital Management, LP reported 44 positions worth US$501M. Largest: Avalyn Pharma Inc., Bristol-Myers Squibb Company and BridgeBio Pharma, Inc. What it bought and sold, with each filing.

CompanySharesValue as reportedChangeAs of
Avalyn Pharma Inc.1.7MUS$48.4M+23,021Sep 30, 2026
Bristol-Myers Squibb Company500KUS$31.2M+86,755Sep 30, 2026
BridgeBio Pharma, Inc.425KUS$28M−29,930Sep 30, 2026
Parabilis Medicines, Inc.824KUS$26.6Mno changeSep 30, 2026
Johnson & Johnson99,496US$26.3M−39,450Sep 30, 2026
Arrowhead Pharmaceuticals, Inc.315KUS$20.6MnewSep 30, 2026
Syndax Pharmaceuticals, Inc.1.02MUS$19.2M−192KSep 30, 2026
Definium Therapeutics, Inc.498KUS$19M−64,708Sep 30, 2026
Celcuity Inc.231KUS$18.3MnewSep 30, 2026
Septerna, Inc.454KUS$17.8M−82,137Sep 30, 2026